2019
Plasma bio-adrenomedullin is a marker of acute heart failure severity in patients with acute coronary syndrome
ARRIGO, Mattia, Jiří PAŘENICA, Eva GANOVSKÁ, Marie PAVLUSOVA, Alexander MEBAZAA et. al.Základní údaje
Originální název
Plasma bio-adrenomedullin is a marker of acute heart failure severity in patients with acute coronary syndrome
Autoři
ARRIGO, Mattia (250 Francie, garant), Jiří PAŘENICA (203 Česká republika, domácí), Eva GANOVSKÁ (703 Slovensko), Marie PAVLUSOVA (203 Česká republika) a Alexander MEBAZAA (250 Francie)
Vydání
IJC HEART & VASCULATURE, CLARE, ELSEVIER IRELAND LTD, 2019, 2352-9067
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Kód RIV
RIV/00216224:14110/19:00109543
Organizační jednotka
Lékařská fakulta
UT WoS
000462184100037
Klíčová slova anglicky
Bio-adrenomedullin; Acute coronary syndrome; Acute heart failure; Pulmonary edema
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 11. 5. 2020 09:13, Mgr. Tereza Miškechová
Anotace
V originále
Background: The assessment of acute heart failure (AHF) in patients with acute coronary syndrome (ACS) is challenging. This study tested whether measuring plasma adrenomedullin in patients admitted for ACS provides valuable information regarding the presence of AHF at admission or its occurrence during hospitalization. Methods and results: The study population consisted of 927 prospectively enrolled patients with ACS. Blood samples for the measurement of plasma bio-adrenomedullin (bio-ADM) were collected at admission. Patients with alveolar pulmonary edema and interstitial pulmonary edema on chest radiography at admission had step-wise higher plasma concentrations of bio-ADM compared to patients with no or mild pulmonary congestion: 54.3 +/- 10.6 vs. 27.6 +/- 2.1 vs. 22.5 +/- 0.7 ng/L, overall P < 0.001. Patients with ACS complicated by AHF during the index hospitalization displayed higher plasma bio-ADM concentrations at admission compared to patients without AHF (33.8 +/- 2.7 vs. 21.8 +/- 0.7, P < 0.001): the higher the severity of AHF, the higher plasma bio-ADM concentrations at admission. Patients with cardiogenic shock displayed the highest values. Accordingly, bio-ADM concentrations at admission were associated with a higher risk of occurrence of AHF during index hospitalization (odds ratio 1.018, 95% confidence interval 1.011-1.026, P < 0.001). Conclusions: Plasma adrenomedullin is a marker associated with AHF severity in patients with ACS. (c) 2019 Published by Elsevier B.V.
Návaznosti
MUNI/A/1250/2017, interní kód MU |
|